At the time of writing, Akebia Therapeutics Inc [AKBA] stock is trading at $3.99, up 7.55%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The AKBA shares have gain 11.76% over the last week, with a monthly amount glided 0.50%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Leerink Partners started tracking the stock with Outperform rating on April 28, 2025, and set its price target to $7. On April 01, 2025, Jefferies initiated with a Buy rating and assigned a price target of $6 on the stock. H.C. Wainwright upgraded its rating to a Buy but $3.75 remained the price target by the analyst firm on August 28, 2023. Piper Sandler upgraded its rating to Overweight for this stock on May 31, 2023, and upped its price target to $4. In a note dated March 31, 2022, Piper Sandler downgraded an Neutral rating on this stock and revised its target price from $8 to $2.
For the past year, the stock price of Akebia Therapeutics Inc fluctuated between $0.93 and $4.08. Currently, Wall Street analysts expect the stock to reach $6.5 within the next 12 months. Akebia Therapeutics Inc [NASDAQ: AKBA] shares were valued at $3.99 at the most recent close of the market. An investor can expect a potential return of 62.91% based on the average AKBA price forecast.
Analyzing the AKBA fundamentals
According to Akebia Therapeutics Inc [NASDAQ:AKBA], the company’s sales were 184.91M for trailing twelve months, which represents an 75.84% jump. Gross Profit Margin for this corporation currently stands at 0.68% with Operating Profit Margin at -0.12%, Pretax Profit Margin comes in at -0.25%, and Net Profit Margin reading is -0.25%. To continue investigating profitability, this company’s Return on Assets is posted at -0.15, Equity is 1.67 and Total Capital is -0.1. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.80 points at the first support level, and at 3.62 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.09, and for the 2nd resistance point, it is at 4.20.
Ratios To Look Out For
It is important to note that Akebia Therapeutics Inc [NASDAQ:AKBA] has a current ratio of 2.23. As well, the Quick Ratio is 2.02, while the Cash Ratio is 1.24. Considering the valuation of this stock, the price to sales ratio is 5.67, the price to book ratio is 42.47.
Transactions by insiders
Recent insider trading involved Ostrowski Erik, SVP, CFO, CBO & Treasurer, that happened on Jun 30 ’25 when 41314.0 shares were sold. Officer, Ostrowski Erik completed a deal on Jun 30 ’25 to buy 41314.0 shares. Meanwhile, SVP, Chief Accounting Officer Malabre Richard C sold 15000.0 shares on Jun 09 ’25.
